Exploring plasma cell motility and extracellular matrix protein biomarkers for primary progressive multiple sclerosis: A pilot study
Lackey, E.; Reinke, S.; Luo, S.; Laskowitz, D.; Eckstein, C.; Gregory, S.
Show abstract
Primary progressive multiple sclerosis is associated with neurodegeneration and chronic inflammation, and results in the accumulation of gradual disability. This pilot study investigated 92 plasma proteins using proximal extension assay to identify MS subtype-specific biomarkers with a focus on predicting primary progressive MS. We analyzed samples from 66 MS patients (22 relapsing-remitting, 22 secondary progressive, and 22 primary progressive) and 22 controls. ANOVA identified five proteins (ACAN, TMSB10, BST1, CLEC11A, MYOC) with p < 0.05 for differentiating phenotypes of MS, four of which have been previously implicated in MS pathophysiology. However, after correcting for multiple comparisons no individual proteins remained statistically significant. Logistic regression and support vector models using these 5 proteins for predicting primary progressive, in one-vs all-models, against other MS phenotypes and controls were of low accuracy (0.69 and 0.68, respectively). While not immediately translatable, these results lay the groundwork for future studies into MS progression biomarkers.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis cohort population structure and disease etiology 95%
- Current status and future opportunities in modeling Multiple Sclerosis clinical characteristics 94%
- Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis 93%
Similar papers in this journal
- Humoral and cellular immune responses to SARS CoV-2 vaccination in Persons with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments 95%
- COVID-19 is associated with multiple sclerosis exacerbations that are prevented by disease modifying therapies 92%
- Response to COVID-19 booster vaccinations in seronegative people with MS. 92%
Similar papers in this journal
- Frequency and Potential Risk Factors Associated with the Development of Asymptomatic T2 Hyperintense Cervical Spine Lesions on MRI in Patients with Relapsing-Remitting Multiple Sclerosis 96%
- Multiple Sclerosis Cognitive Scale (MSCS): A Brief Psychometrically-Robust Metric of Patient-Reported Cognitive Difficulty 95%
- Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical outcomes in multiple sclerosis: a retrospective cross-sectional study 94%
Similar papers in this journal
Similar papers in this journal
- Evolution of Chronic Lesion Tissue in RRMS patients: An association with disease progression 93%
- CSF of SARS-CoV-2 patients with neurological syndromes reveals hints to understand pathophysiology 93%
- Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosis 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.